Fate Therapeutics Inc (NASDAQ: FATE) started the day on Thursday, with a price decrease of -4.59% at $0.99, before settling in for the price of $1.04 at the close. Taking a more long-term approach, FATE posted a 52-week range of $0.66-$3.50.
The Healthcare sector firm’s twelve-monthly sales growth has been -2.63% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was -2.63%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 29.37%. This publicly-traded company’s shares outstanding now amounts to $114.66 million, simultaneously with a float of $109.67 million. The organization now has a market capitalization sitting at $114.44 million. At the time of writing, stock’s 50-day Moving Average stood at $1.2255, while the 200-day Moving Average is $1.1593.
Fate Therapeutics Inc (FATE) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Fate Therapeutics Inc’s current insider ownership accounts for 4.97%, in contrast to 69.05% institutional ownership. According to the most recent insider trade that took place on Aug 04 ’25, this organization’s insider sold 9,037 shares at the rate of 1.06, making the entire transaction reach 9,573 in total value, affecting insider ownership by 397,670. Preceding that transaction, on Aug 04 ’25, Company’s President and CEO sold 14,466 for 1.06, making the whole transaction’s value amount to 15,396. This particular insider is now the holder of 334,898 in total.
Fate Therapeutics Inc (FATE) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.3 per share during the current fiscal year. Fate Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 29.37% and is forecasted to reach -1.16 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 11.23% through the next 5 years, which can be compared against the -2.63% growth it accomplished over the previous five years trading on the market.
Fate Therapeutics Inc (NASDAQ: FATE) Trading Performance Indicators
Let’s observe the current performance indicators for Fate Therapeutics Inc (FATE). It’s Quick Ratio in the last reported quarter now stands at 8.04. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 13.51.
In the same vein, FATE’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.45, a figure that is expected to reach -0.27 in the next quarter, and analysts are predicting that it will be -1.16 at the market close of one year from today.
Technical Analysis of Fate Therapeutics Inc (FATE)
If we take a close look at the recent performances of Fate Therapeutics Inc (NASDAQ: FATE), its last 5-days Average volume was 1.56 million that shows plunge from its year to date volume of 2.09 million. During the previous 9 days, stock’s Stochastic %D was recorded 11.54% While, its Average True Range was 28.55.
Raw Stochastic average of Fate Therapeutics Inc (FATE) in the period of the previous 100 days is set at 7.99%, which indicates a major rise in contrast to 1.28% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 0.1433 that was higher than 0.1024 volatility it exhibited in the past 100-days period.
